9
Views
11
CrossRef citations to date
0
Altmetric
Research Article

Pharmacokinetics of Bay g 2821 in the dog and in man

Pages 564-573 | Received 29 Jan 1977, Published online: 07 Aug 2008

References

  • Berg K. J., Jerstad S., Tromsdal A. Studies on the clinical pharmacology of a new potent diuretic, Bay g 2821. Pharmatherapeutica 1976; 1: 3191. Berg K. J., Jerstad S., Tromsdal A. Studies on the clinical pharmacology of a new potent diuretic, Bay g 2821. Pharmatherapeutica 1976; 1: 319
  • Hoppe-Seyler G. Personal communication 19762. Hoppe-Seyler g. Personal communication 1976
  • Loew D. Diuretic action of Bay g 2821 in oedema-free volunteers. Curr. Med. Res. Opin. 1977; 4: 4553. Loew D. Diuretic action of Bay g 2821 in oedema-free volunteers. Curr. Med. Res. Opin. 1977; 4: 455
  • Loew D., Meng K. The renal mechanism of Bay g 2821. Pharmatherapeutica 1977; 1: 3334. Loew D., Meng K. The renal mechanism of Bay g 2821. Pharmatherapeutica 1977; 1: 333
  • Meng K., Loew D., Stoepel K., Hoffmeister F. Pharmacology of Bay g 2821, long-acting, high ceiling diuretic. Curr. Med. Res. Opin. 1977; 4: 5555. Meng K., Loew D., Stoepel K., Hoffmeister F. Pharmacology of Bay g 2821, long-acting, high ceiling diuretic. Curr. Med. Res. Opin. 1977; 4: 555
  • Moller E., Horstmann H., Meng K., Loew D. 3-amino-1-(3, 4-dichlor-α-methyl-benzyl)-2 pyrazolin-5-one (Bay g 2821), a potent diuretic from a new substance class. Experientia. 1977, In Press6. Moller E., Horstmann H., Meng K., Loew D. 3-amino-1-(3, 4-dichlor-α-methyl-benzyl)-2 pyrazolin-5-one (Bay g 2821), a potent diuretic from a new substance class. Experientia. 1977, In Press
  • Mussche M., Lameire N. The mechanism of action of Bay g 2821: a new diuretic. Curr. Med. Res. Opin. 1977; 4: 4627. Mussche M., Lameire N. The mechanism of action of Bay g 2821: a new diuretic. Curr. Med. Res. Opin. 1977; 4: 462

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.